GSK1324726A-I-BET726-DataSheet-生命科學試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEGSK1324726ACat. No.: HY-13960CAS No.: 1300031-52-0Synonyms: I-BET726分式: CHClNO分量: 434.91作靶點: Epigenetic Reader Domain作通路: Epigenetics儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 46 mg/mL

2、 (105.77 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.2993 mL 11.4966 mL 22.9933 mL5 mM 0.4599 mL 2.2993 mL 4.5987 mL10 mM 0.2299 mL 1.1497 mL 2.2993 mL請根據產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內實驗 請根據您的實驗動物和給藥式選擇適當的溶解案，配制前請先配制澄清的儲備液，再依次添加助溶劑(為保證

3、實驗結果的可靠性，體內實驗的作液，建議您現現配，當天使；澄清的儲備液可以根據儲存條件，適當保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.75 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (5.75 mM); Clear solution1/3 Master of Small Molecules 您邊的抑制劑師www

4、.MedChemEBIOLOGICAL ACTIVITY物活性 GSK1324726A種有效的選擇性 BET 蛋抑制劑，親和結合到 BRD2 (IC50=41 nM)，BRD3 (IC50=31nM) 和 BRD4 (IC50=22 nM)。IC50 & Target IC50: 22 nM (BRD4), 31 nM (BRD3), 41 nM (BRD2) 1體外研究 A panel of neuroblastoma cell lines are treated with GSK1324726A (I-BET726), and observed potent growthinhibitio

5、n and cytotoxicity in most cell lines irrespective of MYCN copy number or expression level. Allneuroblastoma cell lines tested exhibit potent growth inhibition, with a median growth IC50 value (gIC50;inhibitor concentration resulting in 50% growth inhibition) equal to 75 nM 1.體內研究 GSK1324726A (I-BET

6、726) inhibits neuroblastoma tumor growth. In the SK-N-AS model, mice in the vehiclegroup are euthanized on day 14 due to large tumor size. While there is no significant difference in tumorgrowth between the vehicle and GSK1324726A (5 mg/kg) group, 58% tumor growth inhibition (TGI) isobserved in the

7、GSK1324726A (15 mg/kg) group on day 14 of the study (n=9; p=0.006). Mice in theGSK1324726A (15 mg/kg) group are treated for an additional 7 days before tumor volume reaches a levelcomparable to that observed in the vehicle group, at which point the study is terminated. Tumors in the CHP-212 model gr

8、ow much more slowly. After 42 days, tumors in vehicle-treated mice are only half the size thosein the SK-N-AS model at the end of the study (Day 14). In the CHP-212 model, treatment with 5 mg/kgGSK1324726A results in TGI equal to 50% (n=8; p=0.1816), and mice in the 15 mg/kg group exhibits a TGIof 8

9、2% at the end of the study (n=5; p=0.0488) 1.PROTOCOLCell Assay 1 Cell line growth-death assays are performed with a few modifications. Briefly, cells are seeded into 384-wellor 96-well plates at a density optimized for 6 days of growth. The following day, T0 measurements are takenusing CellTiter-Gl

10、o, CellTiter-Fluor, or CyQuant Direct. Plates are read on an Envision, Safire 2, orSpectraMax Gemini EM plate reader. Remaining plates are treated with DMSO or a titration ofGSK1324726A. Cells are incubated for 6 days and developed. Results are plotted as a percentage of the T0value, normalized to 1

11、00%, versus concentration of compound. A 4-parameter equation is used to generateconcentration response curves. Growth IC50 (gIC50) values are calculated at the mid-point of the growthwindow (between DMSO and T0 values). Ymin-T0 values are calculated by subtracting the T0 value (100%)from the Ymin v

12、alue on the curve, and are a measure of net population cell growth or death 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 12 CHP-212 (1107) or SK-N-AS (5106) cells in 100% matrigel are implanted subcutaneously into the ri

13、ghtflank of approximately 9 week old female nude (Crl:CD-1-Foxn1 nu) mice. Tumors are measured withcalipers and randomized using stratified sampling according to tumor size into treatment groups of 10 mice.GSK1324726A in vehicle or vehicle alone is administered orally by individual body weight at 10

14、mls/kg. Miceare weighed and tumors are measured with calipers twice weekly, and mice are observed daily for any2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEadverse treatment affects. Mice are euthanized using CO2 inhalation according to AVMA guidelines after twoconsecutive tumor measurements gre

15、ater than 2500mm3, or if body weight loss greater than 20% isobserved. For mouse pharmacodynamic studies, mice are euthanized as described above. Tumors areharvested from euthanized mice and placed in RNAlater for RNA isolation. Blood is collected aftereuthanasia via cardiac puncture.Rats 2Male CD r

16、ats (253-283 g) are surgically prepared with implanted cannulae in the femoral vein (forGSK1324726A administration) and jugular vein (for blood sampling). Each rat receives Duphacillin (100mg/kg s.c.) and Carprofen (7.5 mg/kg s.c.) as a pre-operative antibiotic and analgesic respectively. Each ratis

17、 allowed to recover for at least 2 days prior to dosing. Rats have free access to food and water throughout.Rat PK studies are conducted as a crossover design over 2 dosing occasions, with 3 days between doseadministrations. Serial blood samples are taken (via indwelling jugular cannula) up to 26 h

18、post doseadministration on both dosing occasions. On study day 1, n=3 male rats each receives a 1 h intravenousinfusion of GSK1324726A formulated in DMSO and 10% (w/v) KleptoseTM in saline (2%:98%) at aconcentration of 0.2 mg/mL and the dose is filtered using a ca. 0.2 m syringe filter unit. GSK1324

19、726A isadministered as a 1 h i.v. infusion at 5 mL/kg/h to achieve a target dose of 1 mg/kg. On study day 2, thesame three rats each receives an oral administration of GSK1324726A suspended in 3% Pharmacoat603/0.2% Sodium Lauryl Sulphate (w/v) aq. at a concentration of 0.6 mg/mL administered by gava

20、ge at 5mL/kg to achieve a target dose of 3 mg/kg. At the end of the study the rats are euthanised by administrationof sodium pentobarbital through the jugular vein cannula.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產品發(fā)表的科研獻 Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. J Med Chem. 2018 Jan 25;61(2):504-513. Bioorg Med Chem